Reuters reported on Feb. 6, 2019, that pain is by far the top reason why U.S. patients seek out medical cannabis. Word of mouth is a primary factor in people seeking cannabis medicine to soothe their pain, and there are ample studies to support these anecdotal reports. It is unclear whether CBD in the absence of other cannabinoids and terpenes can provide a remedy to neuropathy.
“CBD may offer an option for treating different types of chronic pain,” he wrote. “A study from the European Journal of Pain showed, using an animal model, CBD applied on the skin could help lower pain and inflammation due to arthritis.
Dr. Laszlo Mechtler, medical director of the Dent Neurologic Institute in Amherst, New York, served as senior researcher for a study of 204 adults ages 75 and older who took cannabis to ease various aches and pains. Seventy percent of the patients experienced pain relief, while one-third of the patients also reported reduced dependency on opioid painkillers.
Among patients who used cannabis as a direct strategy to manage their lupus symptoms, 83% said they would recommend it to another person with lupus. Yet 96% of respondents reported that their doctors had not talked with them about using cannabis to treat lupus, which indicates that most people are seeking out medical marijuana on their own.
A 2012 literature review published in the Journal of Experimental Medicine examined at least one way that cannabinoids suppress inflammatory and neuropathic pain, by targeting alpha-3 glycine receptors. Citing the difficulty of treating neuropathic pain, the researchers also noted that CBD might be able to address the persistent discomfort associated with a range of diseases.
Methods: In total, 29 patients with symptomatic peripheral neuropathy were recruited and enrolled. 15 patients were randomized to the CBD group with the treatment product containing 250 mg CBD/3 fl. oz, and 14 patients were randomized to the placebo group. After four weeks, the placebo group was allowed to crossover into the treatment group. The Neuropathic Pain Scale (NPS) was administered biweekly to assess the mean change from baseline to the end of the treatment period.
Results: The study population included 62.1% males and 37.9% females with a mean age of 68 years. There was a statistically significant reduction in intense pain, sharp pain, cold and itchy sensations in the CBD group when compared to the placebo group. No adverse events were reported in this study.
Background: Peripheral neuropathy can significantly impact the quality of life for those who are affected, as therapies from the current treatment algorithm often fail to deliver adequate symptom relief. There has, however, been an increasing body of evidence for the use of cannabinoids in the treatment of chronic, noncancer pain. The efficacy of a topically delivered cannabidiol (CBD) oil in the management of neuropathic pain was examined in this four-week, randomized and placebocontrolled trial.
Conclusion: Our findings demonstrate that the transdermal application of CBD oil can achieve significant improvement in pain and other disturbing sensations in patients with peripheral neuropathy. The treatment product was well tolerated and may provide a more effective alternative compared to other current therapies in the treatment of peripheral neuropathy.
Keywords: CBD; cannabis sativa; diabetic neuropathy; hemp; nerve pain; review..